AGMB (AGMB) Stock Price & Analysis
AGMB (AGMB) fell 4.95% to USD 9.8 as of June 10, 2026 at 12:34 UTC, according to Nexqual real-time market data.
AGMB last closed at USD 10.31; the session ranged USD 9.25–10.61 on volume of 132,041 shares. Market capitalization is $482.63M, with a 52-week range of USD 8.75–17.45 (NMS). Source: Nexqual, June 10, 2026 at 12:34 UTC.
Key Statistics (as of June 10, 2026 at 12:34 UTC)
| Price | USD 9.8 |
|---|---|
| Change | ▼ 4.95% (down) |
| Previous Close | USD 10.31 |
| Open | USD 10.5 |
| Day Range | USD 9.25 – 10.61 |
| 52-Week Range | USD 8.75 – 17.45 |
| Volume | 132,041 shares |
| Market Cap | $482.63M |
| Exchange | NMS |
Technical Analysis (AGMB)
Nexqual's technical model rates AGMB "STRONG SELL" based on 0 bullish and 5 bearish signals across 84 daily candles, as of June 10, 2026 at 12:34 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.73 (neutral) |
| vs SMA50 | Below (USD 11.08) |
| MACD | -0.12 (negative) |
Analyst Ratings (AGMB)
Wall Street analysts rate AGMB "None" based on 3 analysts, with a mean price target of USD 32 (range USD 28–36), per Nexqual as of June 10, 2026 at 12:34 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 32 |
| High Target | USD 36 |
| Low Target | USD 28 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (AGMB)
| EPS Estimate | USD -0.41 |
|---|---|
| Revenue Estimate | $0 |
Source: Nexqual, June 10, 2026 at 12:34 UTC.
Financials & Fundamentals (AGMB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -39.22% |
| Debt / Equity | 0.96 |
| Current Ratio | 6.52 |
| Total Cash | $116.51M |
| Total Debt | $1.25M |
| Free Cash Flow | $-24.37M |
Source: Nexqual, June 10, 2026 at 12:34 UTC.
Financial Health Score (AGMB)
Nexqual rates AGMB's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 12:34 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $117M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$52M |
| Efficiency | Critical — ROE -39%, ROA -20.6% |
Ownership (AGMB)
| Insider Ownership | +5.90% |
|---|---|
| Institutional Ownership | +48.35% |
| Shares Outstanding | 49.25M |
| Float | 16.41M |
| Short % of Float | +1.94% |
Source: Nexqual, June 10, 2026 at 12:34 UTC.
Leadership (AGMB)
AGMB is led by Tim Knotnerus MSc (age 42), CEO & Executive Director, per Nexqual as of June 10, 2026 at 12:34 UTC.
| CEO & Executive Director | Tim Knotnerus MSc (age 42) |
|---|---|
| Chief Financial Officer | Pierre Kemula B.Sc. (age 51) |
| Vice President of Investor Relations | Sofie Van Gijsel |
Major Backers & Investors (AGMB)
Notable institutional backers of AGMB include Eqt Fund Management S.a R.l., Sanofi, Cormorant Asset Management, LP, according to Nexqual as of June 10, 2026 at 12:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Eqt Fund Management S.a R.l. | 10.44% |
| Sanofi | 5.65% |
| Cormorant Asset Management, LP | 5.01% |
| TCG Crossover Management, LLC | 4.17% |
| Federated Hermes, Inc. | 3.33% |
| Casdin Capital, LLC | 3.15% |
| Andera Partners | 3.12% |
| FMR, LLC | 2.96% |
Source: Nexqual, June 10, 2026 at 12:34 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EIKN | Eikon Therapeutics, Inc. | USD 8.77 | ▼ 2.12% |
| MANE | Veradermics, Incorporated | USD 95.91 | ▲ 4.6% |
| COAG | Hemab Therapeutics Holdings, In | USD 27 | ▲ 6.72% |
| SPTX | Seaport Therapeutics, Inc. | USD 17.66 | ▲ 7.42% |
| EVMN | Evommune, Inc. | USD 20.49 | ▲ 2.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 12:34 UTC. This page is informational and not investment advice.